ALNY has been the subject of several other reports. Barclays restated a buy rating and set a $125.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, August 7th. Piper Jaffray Companies lifted their price target on Alnylam Pharmaceuticals from $142.00 to $145.00 and gave the stock an overweight rating in a research note on Tuesday, September 3rd. Goldman Sachs Group reaffirmed a neutral rating and issued a $80.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, May 23rd. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $126.00 to $124.00 and set an overweight rating for the company in a research report on Wednesday, August 7th. Finally, UBS Group increased their price objective on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a neutral rating in a research note on Wednesday, September 4th. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $116.13.
Alnylam Pharmaceuticals stock opened at $84.27 on Friday. The firm has a fifty day simple moving average of $79.52 and a two-hundred day simple moving average of $78.84. The company has a quick ratio of 6.16, a current ratio of 6.28 and a debt-to-equity ratio of 0.17. Alnylam Pharmaceuticals has a twelve month low of $60.27 and a twelve month high of $103.50. The company has a market capitalization of $8.88 billion, a PE ratio of -11.13 and a beta of 2.35.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.06) by $0.04. The firm had revenue of $38.20 million for the quarter, compared to analysts’ expectations of $42.24 million. Alnylam Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 848.70%. The company’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.61) earnings per share. As a group, equities analysts expect that Alnylam Pharmaceuticals will post -8.21 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its holdings in Alnylam Pharmaceuticals by 41.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 225,148 shares of the biopharmaceutical company’s stock worth $16,412,000 after buying an additional 66,253 shares during the period. Geode Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 915,533 shares of the biopharmaceutical company’s stock worth $66,708,000 after buying an additional 34,770 shares during the last quarter. Quadrant Capital Group LLC grew its position in shares of Alnylam Pharmaceuticals by 543.2% in the 1st quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 440 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Alnylam Pharmaceuticals by 3.4% during the first quarter. Janus Henderson Group PLC now owns 25,243 shares of the biopharmaceutical company’s stock valued at $2,360,000 after buying an additional 841 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Rhumbline Advisers now owns 92,891 shares of the biopharmaceutical company’s stock valued at $8,681,000 after buying an additional 2,295 shares during the period. Institutional investors own 94.26% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Article: The primary rules of Elliott Wave theory
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.